Integration of novel agents into first-line therapy for newly diagnosed multiple myeloma (MM) patients who are eligible to receive an autologous stem cell transplantation (ASCT) has led to unprecedented rates of high-quality responses.1 Based on the results of several phase III trials,2, 3, 4, 5 a three-drug induction regimen including bortezomib and dexamethasone (VD) is currently considered the standard of care in preparation for ASCT. The European Medicines Agency recently approved the combination of bortezomib with thalidomide and dexamethasone (VTD) for this use.

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

CAVO, MICHELE;PANTANI, LUCIA;PEZZI, ANNALISA;MARZOCCHI, GIULIA;ZAMAGNI, ELENA;GAMBERI, BARBARA;TACCHETTI, PAOLA;BRIOLI, ANNAMARIA;
2015

Abstract

Integration of novel agents into first-line therapy for newly diagnosed multiple myeloma (MM) patients who are eligible to receive an autologous stem cell transplantation (ASCT) has led to unprecedented rates of high-quality responses.1 Based on the results of several phase III trials,2, 3, 4, 5 a three-drug induction regimen including bortezomib and dexamethasone (VD) is currently considered the standard of care in preparation for ASCT. The European Medicines Agency recently approved the combination of bortezomib with thalidomide and dexamethasone (VTD) for this use.
Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/528929
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 44
social impact